Home » Topics » Regulatory » EMA

EMA
RSS

EMA committee hands down positive opinion on burosumab for X-linked hypophosphatemia

Dec. 18, 2017

CHMP grants positive opinion to Cx601 for the treatment of perianal fistulas in Crohn's disease

Dec. 18, 2017

EMA's CHMP requests additional information for betrixaban MAA

Dec. 13, 2017

EMA validates application for Opdivo plus Yervoy in advanced renal cell carcinoma

Dec. 1, 2017

EMA gives orphan drug designation to ProQR Therapeutics' QR-313

Nov. 30, 2017

EMA grants orphan drug designation for DCC-2618 as treatment of gastrointestinal stromal tumors

Nov. 30, 2017

EMA accepts Tagrisso submission in first-line EGFR-mutated NSCLC

Nov. 28, 2017

EMA accepts Macrilen MAA for adult growth hormone deficiency

Nov. 28, 2017

EMA launches improved version of EudraVigilance system for safety monitoring

Nov. 22, 2017

EMA announces relocation to the Netherlands

Nov. 21, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...